The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
RxDx is a chain of primary care driven multispecialty healthcare clinics with two main branches situated in Whitefield and Malleswaram in Bengaluru
Eka Care will provide a six-month complimentary trial period to all members who register before December 31, 2021
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
This award is open to all currently operational laboratories pertaining to testing, calibration & medical including their proficiency testing providers & reference material producers located in India
Barbara Engelhardt moves her computational and statistics lab to Gladstone
The document is a global recommendation for circular packaging design. It will be updated and adapted to changes in the collection, sorting and recycling technology, as well as to future material development
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
Subscribe To Our Newsletter & Stay Updated
